Survey of 878 fibromyalgia patients finds most use low-dose CBD with no clear dose-response relationship
Among 878 people with fibromyalgia using CBD, typical doses were under 50 mg/day, one-third did not know their dose, purchasing was driven by personal research rather than medical advice, and higher doses did not correlate with greater reported benefit.
Quick Facts
What This Study Found
Average CBD dose per session was 16 mg, with 24-27 mg per day. About one-third of participants did not know their CBD dose. Purchasing was driven by personal research (63%) rather than medical professionals (16%). Tinctures and topicals were most common. Those using both inhalation and non-inhalation routes reported greater symptom relief. No consistent relationship between CBD dose and reported effects was found.
Key Numbers
878 participants (93.6% female, mean age 55.5); 16 mg CBD per session, 24-27 mg/day average; 63% relied on personal research; 16% guided by medical professionals; ~33% did not know their dose.
How They Did This
Secondary analysis of a cross-sectional survey of 878 people with fibromyalgia using CBD products. Participants were subgrouped by past-year high-THC cannabis (HTC) use. Administration routes, dosing patterns, and perceived effects were analyzed.
Why This Research Matters
With fibromyalgia patients commonly turning to CBD products, this study reveals that most are self-directing their treatment with low doses and no medical guidance, and that standard dose-response assumptions may not apply.
The Bigger Picture
The lack of a dose-response relationship for CBD in fibromyalgia raises important questions: are patients underdosing, or is the reported benefit largely driven by expectancy? This finding should inform clinical trial design.
What This Study Doesn't Tell Us
Self-report data. No verification of product contents or diagnoses. Cross-sectional design. Predominantly female and white sample. No placebo control. CBD product quality and actual cannabinoid content likely varied.
Questions This Raises
- ?Would higher, verified doses of CBD produce measurable dose-response effects?
- ?Is the benefit driven by expectancy, the entourage effect from other cannabinoids, or genuine CBD pharmacology at low doses?
Trust & Context
- Key Stat:
- No dose-response relationship for CBD at typical doses under 50 mg/day
- Evidence Grade:
- Large survey with detailed dosing data, but self-report and lack of verified products limit conclusions.
- Study Age:
- Published in 2022.
- Original Title:
- Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.
- Published In:
- The journal of pain, 23(1), 45-54 (2022)
- Authors:
- Boehnke, Kevin F(22), Gagnier, Joel J(3), Matallana, Lynne(4), Williams, David A
- Database ID:
- RTHC-03719
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
How much CBD do fibromyalgia patients typically take?
Most used less than 50 mg per day, with an average of 16 mg per session and 24-27 mg per day. Notably, about one-third of users did not know what dose they were taking.
Does taking more CBD provide more relief for fibromyalgia?
In this survey, there was no consistent relationship between higher CBD doses and greater reported benefit. The researchers suggest this could be due to expectancy effects, individual variability, or the doses being too low to see a pharmacological dose-response.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03719APA
Boehnke, Kevin F; Gagnier, Joel J; Matallana, Lynne; Williams, David A. (2022). Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.. The journal of pain, 23(1), 45-54. https://doi.org/10.1016/j.jpain.2021.06.007
MLA
Boehnke, Kevin F, et al. "Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.." The journal of pain, 2022. https://doi.org/10.1016/j.jpain.2021.06.007
RethinkTHC
RethinkTHC Research Database. "Cannabidiol Product Dosing and Decision-Making in a National..." RTHC-03719. Retrieved from https://rethinkthc.com/research/boehnke-2022-cannabidiol-product-dosing-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.